Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
60 people get BSTC articles and Market Currents by email alert.
Get email alerts on BSTC »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
PR Newswire (May 10, 2013)
-
PR Newswire (Mar 12, 2013)
-
PR Newswire (Feb 27, 2013)
-
PR Newswire (Jan 7, 2013)
-
PR Newswire (Nov 15, 2012)
-
PR Newswire (Nov 8, 2012)
-
5 Low-Debt Biotech Stocks Forecasted For GrowthZetaKap • Sat, Sep 22, 2012 -
PR Newswire (Sep 13, 2012)
-
PR Newswire (Sep 5, 2012)
-
PR Newswire (Sep 4, 2012)
-
PR Newswire (Aug 29, 2012)
To learn more about Seeking Alpha Pro, click here.
There are no Focus articles on BSTC.
-
5 Low-Debt Biotech Stocks Forecasted For GrowthZetaKap • Sat, Sep 22, 2012
-
8 Highly Liquid Healthcare Stocks Undervalued By EPS TrendsKapitall • Thu, Aug 23, 2012 -
-
5 Analyst-Backed Healthcare Small Caps Commanding Strong ProfitsZetaKap • Wed, Jul 18, 2012
-
-
-
-
Short-Sellers Expect These 14 Biotechs To OutperformKapitall • Thu, Jan 5, 2012
-
-
-
11 Biotech Stocks With Bullish Short TrendsKapitall • Wed, Nov 23, 2011
-
-
Best Performing Stocks Since 3/9/09 and 10/9/07Bespoke Investment Group • Thu, Nov 12, 2009 -
-
PR Newswire (May 10, 2013)
-
PR Newswire (Mar 12, 2013)
-
PR Newswire (Feb 27, 2013)
-
PR Newswire (Jan 7, 2013)
-
PR Newswire (Nov 15, 2012)
-
PR Newswire (Nov 8, 2012)
-
PR Newswire (Sep 13, 2012)
-
PR Newswire (Sep 5, 2012)
-
PR Newswire (Sep 4, 2012)
-
PR Newswire (Aug 29, 2012)
-
PR Newswire (Aug 9, 2012)
BSTC vs. ETF Alternatives
Company Description
Currently, there's no company description for BSTC.
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Tuesday, March 12, 4:21 PM BioSpecifics (BSTC): Q4 EPS of $0.16. Revenue of $3.5M misses by $1.84M. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Tuesday, February 5, 11:29 AM Auxilium Pharmaceuticals (AUXL +0.3%) and strategic partner BioSpecifics (BSTC +1.3%) both move up after The Journal of Urology publishes its Impress Study, a Phase 3 trial of Xiaflex for the treatment of Peyronie's disease, which is an excess of inelastic collagen causing penile curvature deformity. AUXL previously announced positive top-line efficacy and safety results of the studies' co-primary endpoints, and based on the new results, has submitted a supplemental Biologics License Application (sBLA) to the FDA. Comment! [Healthcare, On the Move]